Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03690765 |
|
Recruitment Status :
Completed
First Posted : October 1, 2018
Last Update Posted : December 28, 2021
|
Sponsor:
Abbott
Information provided by (Responsible Party):
Abbott
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
A non-interventional, observational program to assess the effects of dydrogesterone (Duphaston®) 6-months-administration in patients with confirmed endometriosis in a post-marketing setting in the Russian Federation
| Condition or disease | Intervention/treatment |
|---|---|
| Endometriosis | Drug: Duphaston® (Dydrogesterone) |
A non-interventional, observational program to assess the effects of oral dydrogesterone therapy in a post-marketing setting whether the effects are related to the regimen of dydrogesterone therapy. In this observational program, assuming that dydrogesterone plays a role in the treatment of endometriosis without suppression of ovulation, the goal is to observe the possible implications of such treatment in terms of treatment regimen and response pattern. In the study will be described effects of Duphaston® 6-months-administration in patients with confirmed endometriosis by assessing pain relief, quality of life, need of self-medication with analgesics, etc.
| Study Type : | Observational |
| Actual Enrollment : | 350 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Observational Open-Label Multicenter Study of Real Clinical Practice to Evaluate the Effects of Hormonal Therapy With Oral Dydrogesterone for Treatment of Confirmed Endometriosis (ORCHIDEA) |
| Actual Study Start Date : | September 27, 2018 |
| Actual Primary Completion Date : | November 10, 2019 |
| Actual Study Completion Date : | May 29, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Endometriosis
| Group/Cohort | Intervention/treatment |
|---|---|
|
Endometriosis/Dydrogesterone
Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®
|
Drug: Duphaston® (Dydrogesterone)
No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only. Drug: Duphaston® (Dydrogesterone) No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only. |
Primary Outcome Measures :
- Change in chronic pelvic pain intensity [ Time Frame: 6 months ]The changes in chronic pelvic pain intensity assessed by 11-items Numerous Rating Scale (NRS) at the end of observation (Visit 3) versus Baseline (Visit 1) in the prolonged cyclic regime and the continuous regime of Duphaston in patients with endometriosis. The 11-items Numerous Rating Scale (NRS) contains the range from 0 to 10, where 0 represents 'no pain' and 10 represents 'the worst pain'. Patients are asked to point the average pain intensity throughout the last month. The negative change corresponds to better result.
Secondary Outcome Measures :
- Change in Quality of Life [ Time Frame: 3 months, 6 months ]Changes in Quality of Life assessed by Short Form-20 (SF-20) at the end of observation (Visit3) versus Baseline (Visit1) in patients with endometriosis. The Short Form-20 (Copyright © the RAND Corporation) consists of 20 questions grouped into two parameters: psychological and physical components of health. The indicators of each scale are compiled in such a way that the higher the value of the indicator (from 0 to 100), the better the score on the chosen parameter.
- Change in chronic pelvic pain intensity [ Time Frame: 3 months, 6 months ]Change in Patient-reported severity of chronic pelvic pain assessed by 11-items NRS after 3-months treatment (Visit2) and after 6-months treatment (Visit3) versus Baseline (Visit1) in patients with endometriosis
- Cycles' duration [ Time Frame: 6 months ]Description of the cycles' duration during 6-months treatment by Duphaston® in patients with endometriosis
- Change in dysmenorrhea [ Time Frame: 3 months, 6 months ]Description of the changes in dysmenorrhea assessed by 11-items NRS after 3-months treatment (Visit2) and after 6-months treatment (Visit3) versus Baseline (Visit1) in patients with endometriosis. The 11-items Numerous Rating Scale (NRS) contains the range from 0 to 10, where 0 represents 'No symptoms' and 10 represents 'the Worst trouble'. Patients are asked to point the average intensity of dysmenorrhea symptoms (cyclic pelvic pain, mood disorders, gastro-intestinal symptoms etc.) during the last menses period. The negative change corresponds to better result.
- Analgesics using [ Time Frame: 6 months ]A number of days per each cycle (1-6) when analgesics were self-administered
- Sexual wellbeing [ Time Frame: 6 months ]Description of the change in sexual wellbeing assessed by A Quality Assessment of Patient-Reported Outcome Measures for Sexual Wellbeing (5-points Likert scale) at the end of observation (Visit3) versus Baseline (Visit1). A Quality Assessment of Patient-Reported Outcome Measures for Sexual Wellbeing by 5-points Likert scale proposes patients to rate themselves on a 5-point scale as being 'very satisfied, satisfied, ordinarily, rather not satisfied, not satisfied'. The number (and proportion) of patients in each category will be presented.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®
Criteria
Inclusion Criteria:
- Female, aged ≥ 18 years and ≤ 45 years.
- Complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items NRS.
- External genital endometriosis confirmed by laparoscopy.
- Existing pelvic (vaginal) ultrasound data not earlier than 2 months before inclusion in the study.
- Prescribed treatment with Duphaston® according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle or continuously.
- No hormonal treatment in 2 cycles before enrollment.
- Signed Patient Authorization for Use/Disclosure of Data.
Exclusion Criteria:
- Any co-existing disease(s) needing chronic drug therapy (e.g. Crohn's disease, diabetes etc); Severe concomitant medical illness.
- Severe other genital pathology excluding endometriosis (e.g. Multiple/severe myoma; adenomyosis, inflammatory diseases, etc.).
- Routine consumption of analgesics other than for the pain of endometriosis.
- Patients receiving hormonal contraceptives in last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives etc.).
- Ongoing pregnancy.
- Menopause or premature ovarian failure.
- Contraindications to dydrogesterone treatment listed in the locally approved label (Instructions for the medical use of Duphaston®).
- Any other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions and special warnings listed in the locally approved label (Instructions for the medical use of Duphaston®).
- Abnormal results of pap smear test.
- Other conditions that made the patients participation impossible (based on the investigator decision).
- Fertility treatments using assisted reproductive technology.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03690765
Locations
Show 21 study locations
Sponsors and Collaborators
Abbott
Investigators
| Study Chair: | Andrey V Kozachenko, Prof | Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Abbott |
| ClinicalTrials.gov Identifier: | NCT03690765 |
| Other Study ID Numbers: |
DYDR5004 |
| First Posted: | October 1, 2018 Key Record Dates |
| Last Update Posted: | December 28, 2021 |
| Last Verified: | June 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Abbott:
|
endometriosis dydrogesterone Duphaston® progestogens pelvic pain |
Additional relevant MeSH terms:
|
Endometriosis Dydrogesterone Progestins |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |